A prostatic urethral lift does not burn, vaporize, or cut away prostate tissue. Instead, a urologist places small permanent implants that pull obstructing tissue outward and hold the urethral channel open.
The most useful question is not whether UroLift is “good.” It is whether its particular trade—quick recovery and a low rate of new ejaculatory dysfunction in exchange for a less forceful opening and a higher likelihood of another BPH treatment later—matches your priorities and anatomy.
Where it fits best
PUL is most compelling when preserving antegrade ejaculation is a major priority, the prostate anatomy can be mechanically retracted, and the patient accepts that symptom and flow improvement are usually not as strong as with TURP or enucleation.
Prostate size and shape matter more than a single volume cutoff. A long obstructing channel, a very large gland, asymmetric tissue, a high bladder neck, or a substantial middle-lobe configuration may change the plan. FDA labeling includes lateral and median-lobe hyperplasia in men 45 and older and lists prostate volume above 100 cc as a contraindication. Professional-guideline criteria and the strongest comparative evidence have historically been narrower, so “FDA-labeled” and “best-supported for my anatomy” are not identical questions.
What the first two weeks are usually about
Many men leave without a catheter, but catheter-free should never be promised. Swelling, pre-existing retention risk, bladder weakness, bleeding, or the number and location of implants can make short-term catheterization necessary.
Burning, urgency, frequency, pelvic aching, blood in the urine, and a temporarily more irritable stream are common early. The recovery advantage is real for many patients, but it is better described as a shorter inflammatory recovery than as “no recovery.”
Durability and the possibility of another procedure
Five-year follow-up from the pivotal study supports durable average improvement, but PUL has a higher retreatment probability than TURP. Retreatment can mean another PUL, medication restart, or a tissue-removing procedure.
Permanent implants also become part of future procedural planning. HoLEP or another enucleation can still be performed, but implants may be encountered during dissection or morcellation. A patient who wants to keep every future technical pathway as simple as possible should discuss this explicitly before the first implant is placed.
Sexual function: the main reason many men choose it
PUL generally preserves erections and antegrade ejaculation. That does not guarantee that volume, force, sensation, orgasm, or fertility will be unchanged, and baseline sexual symptoms should be documented before treatment.
It is useful to separate “erections” from “ejaculation.” Many BPH discussions blur those outcomes even though a treatment can preserve erectile function while causing dry or retrograde ejaculation.
Capability questions for the treating urologist
- How many PUL procedures have you performed, and how often do your patients need a catheter?
- How do you evaluate and treat obstructive middle-lobe anatomy?
- How many implants do you expect in my case, and what would make you stop or change plans?
- What is your practice's medication-restart or surgical-retreatment rate?
- How would these implants affect HoLEP, MRI interpretation, or another procedure later?
Bottom line
PUL is not a miniature TURP. It is a different bargain: less immediate burden and usually better ejaculatory preservation, with less objective opening and more future-treatment risk.
Sources and evidence
Open the original guideline, regulatory record, or study. Evidence was last checked August 14, 2026.
-
AUA Guideline (2026) Part III: Procedural/Surgical Management The Journal of Urology · professional guideline · 2026
-
Disease Management — Management of Non-neurogenic Male LUTS European Association of Urology · professional guideline · 2026
-
UroLift Advanced Tissue Control System — 510(k) K200441 U.S. Food and Drug Administration · regulatory record · 2020
-
Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study Canadian Journal of Urology · randomized trial follow-up · 2017